| Dr Ray W Ng, DPM | |
|
1105 Central Expy N, Suite # 2300, Allen, TX 75013-6103 | |
| (972) 524-3668 | |
| Not Available |
| Full Name | Dr Ray W Ng |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 37 Years |
| Location | 1105 Central Expy N, Allen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407860430 | NPI | - | NPPES |
| 120396004 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213EP1101X | Podiatrist - Primary Podiatric Medicine | 1070 (Texas) | Primary |
| Provider Name | Ray W Ng Dpm Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1134485311 PECOS PAC ID: 6800057100 Enrollment ID: O20120413000078 |
News Archive
For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
The Todd Cancer Institute (TCI) at Long Beach Memorial Medical Center (LBMMC) and Miller Children's Hospital (MCH) today announced it has been granted approval to proceed with the architecture and engineering for its proton therapy center, becoming one of only 13 centers in the country currently planning for a compact unit.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
People who are successful at exercising regularly don't stop to think about it-they really do, 'Just do it', according to Dr. Sandra Cousins, professor of Physical Education and Recreation at the University of Alberta.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ray W Ng, DPM Po Box 797846, Dallas, TX 75379-7846 Ph: (972) 524-3668 | Dr Ray W Ng, DPM 1105 Central Expy N, Suite # 2300, Allen, TX 75013-6103 Ph: (972) 524-3668 |
News Archive
For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
The Todd Cancer Institute (TCI) at Long Beach Memorial Medical Center (LBMMC) and Miller Children's Hospital (MCH) today announced it has been granted approval to proceed with the architecture and engineering for its proton therapy center, becoming one of only 13 centers in the country currently planning for a compact unit.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
People who are successful at exercising regularly don't stop to think about it-they really do, 'Just do it', according to Dr. Sandra Cousins, professor of Physical Education and Recreation at the University of Alberta.
› Verified 9 days ago
Leslie Campbell, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1111 Raintree Cir Ste 200, Allen, TX 75013 Phone: 972-332-8110 Fax: 972-332-8109 | |
North Texas Foot Group Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1105 Central Expy N Ste 220, Allen, TX 75013 Phone: 972-727-7060 Fax: 972-727-7060 | |
Interventional Partners Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 1105 Central Expy N Ste 2300, Allen, TX 75013 Phone: 972-396-9101 Fax: 972-396-9105 | |
Leslie Campbell, D.p.m., P.a. Podiatrist Medicare: Medicare Enrolled Practice Location: 1105 Central Expy N, Suite 2240, Allen, TX 75013 Phone: 972-747-5800 Fax: 972-747-5831 | |
Texas Partners In Foot And Ankle, Pa Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1780 W. Mcdermott Dr., Suite 200, Allen, TX 75013 Phone: 972-954-1466 | |
Neha Walia Singh, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N Ste 2300, Allen, TX 75013 Phone: 972-396-9101 Fax: 972-396-9105 |